The role of the endocannabinoid system in the neuroendocrine regulation of energy balance

Journal of Psychopharmacology

Volumn 26, Issue 1, 2012, Pages 114-124

  Bermudez Silva, Francisco Javier ^a,b,c,d   Cardinal, Pierre ^a,b   Cota, Daniela ^a,b  

^a INSTITUT FRANÇOIS MAGENDIE   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^d Instituto de Salud Carlos III   (Spain)

Author keywords

CB1; central nervous system; endocannabinoid; energy balance; food intake; hypothalamus; obesity; reward circuits

Indexed keywords

ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR ANTAGONIST; CHOLECYSTOKININ; ENDOCANNABINOID; GHRELIN; GLUCAGON LIKE PEPTIDE 1; GLUCOCORTICOID; HORMONE RECEPTOR BLOCKING AGENT; INSULIN; LEPTIN; MELANOCORTIN RECEPTOR ANTAGONIST; METHANANDAMIDE; NEUROPEPTIDE; NEUROTRANSMITTER; OREXIN; OREXIN 1; PEPTIDE YY; RIMONABANT; UNCLASSIFIED DRUG;

ABDOMINAL OBESITY; ANXIETY DISORDER; BODY WEIGHT; BRAIN FUNCTION; CNR1 GENE; DEPRESSION; DRUG ACTIVITY; DYSLIPIDEMIA; ENERGY BALANCE; FAAH GENE; FOOD INTAKE; GENE PRODUCT; GENETIC VARIABILITY; GLUCOSE HOMEOSTASIS; HORMONE ACTION; HUMAN; HYPOTHALAMUS; LIPID METABOLISM; LIPID PEROXIDATION; METABOLIC DISORDER; METABOLIC REGULATION; METABOLIC SYNDROME X; NERVE CELL MEMBRANE POTENTIAL; NEUROENDOCRINE SYSTEM; NONHUMAN; OBESITY; PANCREAS ISLET; PARAVENTRICULAR THALAMIC NUCLEUS; PATHOGENESIS; PRIORITY JOURNAL; PSYCHOPATHY; PSYCHOPHYSIOLOGY; REVIEW; SENSORY NERVE; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; SOLITARY TRACT NUCLEUS; SUICIDAL IDEATION; VAGAL AFFERENT NEURON; WHITE ADIPOSE TISSUE;

ANIMALS; BODY WEIGHT; EATING; ENDOCANNABINOIDS; ENERGY METABOLISM; HUMANS; HYPOTHALAMUS; NEUROSECRETORY SYSTEMS;

EID: 84856481281     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881111408458     Document Type: Review

References (99)

1. Aberle J, Flitsch J, Beck NA, et al. Genetic variation may influence obesity only under conditions of diet: analysis of three candidate genes. Mol Genet Metab. 2008 ; 95: 188-191
2. Andrews ZB, Liu ZW, Walllingford N, et al. UCP2 mediates ghrelin's action on NPY/AgRP neurons by lowering free radicals. Nature. 2008 ; 454: 846-851
3. Batetta B, Griinari M, Carta G, et al. Endocannabinoids may mediate the ability of (n-3) fatty acids to reduce ectopic fat and inflammatory mediators in obese Zucker rats. J Nutr. 2009 ; 139: 1495-1501
4. Batterham RL, Cowley MA, Small CJ, et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature. 2002 ; 418: 650-654
5. Baye TM, Zhang Y, Smith E, et al. Genetic variation in cannabinoid receptor 1 (CNR1) is associated with derangements in lipid homeostasis, independent of body mass index. Pharmacogenomics. 2008 ; 9: 1647-1656
6. Bellocchio L, Lafenetre P, Cannich A, et al. Bimodal control of stimulated food intake by the endocannabinoid system. Nat Neurosci. 2010 ; 13: 281-283
7. Bensaid M, Gary-Bobo M, Esclangon A, et al. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol. 2003 ; 63: 908-914 (Pubitemid 36368998)
8. Berger A, Crozier G, Bisogno T, et al. Anandamide and diet: inclusion of dietary arachidonate and docosahexaenoate leads to increased brain levels of the corresponding N-acylethanolamines in piglets. Proc Natl Acad Sci USA. 2001 ; 98: 6402-6406 (Pubitemid 32488249)
9. Bermudez-Silva FJ, Suarez Perez J, Nadal A, et al. The role of the pancreatic endocannabinoid system in glucose metabolism. Best Pract Res Clin Endocrinol Metab. 2009 ; 23: 87-102
10. Bermudez-Silva FJ, Viveros MP, McPartland JM, et al. The endocannabinoid system, eating behavior and energy homeostasis: the end or a new beginning?. Pharmacol Biochem Behav. 2010 ; 95: 375-382
11. Berridge KC, Ho CY, Richard JM, et al. The tempted brain eats: pleasure and desire circuits in obesity and eating disorders. Brain Res. 2010 ; 1350: 43-64
12. Bisogno T, Berrendero F, Ambrosino G, et al. Brain regional distribution of endocannabinoids: implications for their biosynthesis and biological function. Biochem Biophys Res Commun. 1999 ; 256: 377-380 (Pubitemid 29298893)
13. Bisogno T, Burston JJ, Rai R, et al. Synthesis and pharmacological activity of a potent inhibitor of the biosynthesis of the endocannabinoid 2-arachidonoylglycerol. ChemMedChem. 2009 ; 4: 946-950
14. Bordicchia M, Battistoni I, Mancinelli L, et al. Cannabinoid CB1 receptor expression in relation to visceral adipose depots, endocannabinoid levels, microvascular damage, and the presence of the Cnr1 A3813G variant in humans. Metabolism. 2010 ; 59: 734-741
15. Breivogel CS, Childers SR. The functional neuroanatomy of brain cannabinoid receptors. Neurobiol Dis. 1998 ; 5: 417-431 (Pubitemid 29075842)
16. Buettner C, Muse ED, Cheng A, et al. Leptin controls adipose tissue lipogenesis via central, STAT3-independent mechanisms. Nat Med. 2008 ; 14: 667-675 (Pubitemid 351809549)
17. Burdyga G, Lal S, Varro A, et al. Expression of cannabinoid CB1 receptors by vagal afferent neurons is inhibited by cholecystokinin. J Neurosci. 2004 ; 24: 2708-2715 (Pubitemid 38380947)
18. Burdyga G, Varro A, Dimaline R, et al. Ghrelin receptors in rat and human nodose ganglia: putative role in regulating CB-1 and MCH receptor abundance. Am J Physiol Gastrointest Liver Physiol. 2006 ; 290: G1289 - G1297
19. Burdyga G, Varro A, Dimaline R, et al. Expression of cannabinoid CB1 receptors by vagal afferent neurons: kinetics and role in influencing neurochemical phenotype. Am J Physiol Gastrointest Liver Physiol. 2010 ; 299: G63 - G69
20. Cani PD, Montoya ML, Neyrinck AM, et al. Potential modulation of plasma ghrelin and glucagon-like peptide-1 by anorexigenic cannabinoid compounds, SR141716A (rimonabant) and oleoylethanolamide. Br J Nutr. 2004 ; 92: 757-761 (Pubitemid 39562153)
21. Cone RD. Anatomy and regulation of the central melanocortin system. Nat Neurosci. 2005 ; 8: 571-578 (Pubitemid 40594196)
22. Cota D. CB1 receptors: emerging evidence for central and peripheral mechanisms that regulate energy balance, metabolism, and cardiovascular health. Diabetes Metab Res Rev. 2007 ; 23: 507-517 (Pubitemid 350018024)
23. Cota D, Marsicano G, Tschop M, et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest. 2003 ; 112: 423-431 (Pubitemid 38063771)
24. Cota D, Proulx K, Seeley RJ. The role of CNS fuel sensing in energy and glucose regulation. Gastroenterology. 2007 ; 132: 2158-2168 (Pubitemid 46693748)
25. Cota D, Sandoval DA, Olivieri M, et al. Food Intake-independent Effects of CB1 Antagonism on Glucose and Lipid Metabolism. Obesity (Silver Spring). 2009 ; 17: 1641-1645
26. Cota D, Tschop MH, Horvath TL, et al. Cannabinoids, opioids and eating behavior: the molecular face of hedonism?. Brain Res Rev. 2006 ; 51: 85-107 (Pubitemid 43782532)
27. Devane WA, Dysarz FAIII, Johnson MR, et al. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol. 1988 ; 34: 605-613 (Pubitemid 19007296)
28. Di Marzo V. Targeting the endocannabinoid system: to enhance or reduce?. Nat Rev Drug Discov. 2008 ; 7: 438-455 (Pubitemid 351649182)
29. Di Marzo V. The endocannabinoid system: its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation. Pharmacol Res. 2009 ; 60: 77-84
30. Di Marzo V, Despres JP. CB1 antagonists for obesity-what lessons have we learned from rimonabant?. Nat Rev Endocrinol. 2009 ; 5: 633-638
31. Di Marzo V, Goparaju SK, Wang L, et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature. 2001 ; 410: 822-825 (Pubitemid 32303781)
32. Di Marzo V, Ligresti A, Cristino L. The endocannabinoid system as a link between homoeostatic and hedonic pathways involved in energy balance regulation. Int J Obes (Lond). 2009a ; 33 2 (Suppl 2). S18 - S24
33. Di Marzo V, Verrijken A, Hakkarainen A, et al. Role of insulin as a negative regulator of plasma endocannabinoid levels in obese and nonobese subjects. Eur J Endocrinol. 2009b ; 161: 715-722
34. Ellis J, Pediani JD, Canals M, et al. Orexin-1 receptor-cannabinoid CB1 receptor heterodimerization results in both ligand-dependent and -independent coordinated alterations of receptor localization and function. J Biol Chem. 2006 ; 281: 38812-38824 (Pubitemid 46042008)
35. European Medicines Agency (2009) European public assessment report (EPAR). Acomplia EPAR summary for the public. Retrieved from http://www.ema.europa.eu/humandocs/Humans/EPAR/acomplia/acomplia.htm (accessed 20 September 2010).
36. Gamber KM, Macarthur H, Westfall TC. Cannabinoids augment the release of neuropeptide Y in the rat hypothalamus. Neuropharmacology. 2005 ; 49: 646-652 (Pubitemid 41208286)
37. Haj-Dahmane S, Shen RY. The wake-promoting peptide orexin-B inhibits glutamatergic transmission to dorsal raphe nucleus serotonin neurons through retrograde endocannabinoid signaling. J Neurosci. 2005 ; 25: 896-905 (Pubitemid 40171005)
38. Harrold JA, Elliott JC, King PJ, et al. Down-regulation of cannabinoid-1 (CB-1) receptors in specific extrahypothalamic regions of rats with dietary obesity: a role for endogenous cannabinoids in driving appetite for palatable food?. Brain Res. 2002 ; 952: 232-238
39. Hentges ST. Synaptic regulation of proopiomelanocortin neurons can occur distal to the arcuate nucleus. J Neurophysiol. 2007 ; 97: 3298-3304 (Pubitemid 47084746)
40. Hentges ST, Low MJ, Williams JT. Differential regulation of synaptic inputs by constitutively released endocannabinoids and exogenous cannabinoids. J Neurosci. 2005 ; 25: 9746-9751 (Pubitemid 41510914)
41. HerkenhamMLynnABJohnsonMRMelvinLSde CostaBRRiceKC (1991) Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci11: 563-583.
42. Herling AW, Kilp S, Elvert R, et al. Increased energy expenditure contributes more to the body weight-reducing effect of rimonabant than reduced food intake in candy-fed wistar rats. Endocrinology. 2008 ; 149: 2557-2566 (Pubitemid 351574492)
43. Hommel JD, Trinko R, Sears RM, et al. Leptin receptor signaling in midbrain dopamine neurons regulates feeding. Neuron. 2006 ; 51: 801-810 (Pubitemid 44374908)
44. Howlett AC, Barth F, Bonner TI, et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev. 2002 ; 54: 161-202 (Pubitemid 34575709)
45. Huang H, Acuna-Goycolea C, Li Y, et al. Cannabinoids excite hypothalamic melanin-concentrating hormone but inhibit hypocretin/orexin neurons: implications for cannabinoid actions on food intake and cognitive arousal. J Neurosci. 2007 ; 27: 4870-4881 (Pubitemid 46699061)
46. Izzo AA, Piscitelli F, Capasso R, et al. Peripheral endocannabinoid dysregulation in obesity: relation to intestinal motility and energy processing induced by food deprivation and re-feeding. Br J Pharmacol. 2009 ; 158: 451-461
47. Jo YH, Chen YJ, Chua SC, et al. Integration of endocannabinoid and leptin signaling in an appetite-related neural circuit. Neuron. 2005 ; 48: 1055-1066
48. Jones D. End of the line for cannabinoid receptor 1 as an anti-obesity target?. Nat Rev Drug Discov. 2008 ; 7: 961-962
49. Katona I, Freund TF. Endocannabinoid signaling as a synaptic circuit breaker in neurological disease. Nat Med. 2008 ; 14: 923-930
50. Kelley AE, Baldo BA, Pratt WE, et al. Corticostriatal-hypothalamic circuitry and food motivation: integration of energy, action and reward. Physiol Behav. 2005 ; 86: 773-795 (Pubitemid 41728993)
51. Kirkham TC, Williams CM, Fezza F, et al. Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol. 2002 ; 136: 550-557 (Pubitemid 34717699)
52. Kola B, Farkas I, Christ-Crain M, et al. The orexigenic effect of ghrelin is mediated through central activation of the endogenous cannabinoid system. PLoS One. 2008 ; 3: e1797
53. Lam TK, Schwartz GJ, Rossetti L. Hypothalamic sensing of fatty acids. Nat Neurosci. 2005 ; 8: 579-584 (Pubitemid 40594197)
54. le Roux CW, Batterham RL, Aylwin SJ, et al. Attenuated peptide YY release in obese subjects is associated with reduced satiety. Endocrinology. 2006 ; 147: 3-8 (Pubitemid 43004254)
55. Leinninger GM, Jo YH, Leshan RL, et al. Leptin acts via leptin receptor-expressing lateral hypothalamic neurons to modulate the mesolimbic dopamine system and suppress feeding. Cell Metab. 2009 ; 10: 89-98
56. Li C, Jones PM, Persaud SJ. Role of the endocannabinoid system in food intake, energy homeostasis and regulation of the endocrine pancreas. Pharmacol Ther. 2011 ; 129: 307-320
57. Lindborg KA, Teachey MK, Jacob S, et al. Effects of in vitro antagonism of endocannabinoid-1 receptors on the glucose transport system in normal and insulin-resistant rat skeletal muscle. Diabetes Obes Metab. 2010 ; 12: 722-730
58. Lipina C, Stretton C, Hastings S, et al. Regulation of MAP kinase-directed mitogenic and protein kinase B-mediated signaling by cannabinoid receptor type 1 in skeletal muscle cells. Diabetes. 2010 ; 59: 375-385
59. Lopez M, Lage R, Saha AK, et al. Hypothalamic fatty acid metabolism mediates the orexigenic action of ghrelin. Cell Metab. 2008 ; 7: 389-399 (Pubitemid 351618114)
60. Mahler SV, Smith KS, Berridge KC. Endocannabinoid hedonic hotspot for sensory pleasure: anandamide in nucleus accumbens shell enhances 'liking' of a sweet reward. Neuropsychopharmacology. 2007 ; 32: 2267-2278 (Pubitemid 47587687)
61. Malcher-Lopes R, Di S, Marcheselli VS, et al. Opposing crosstalk between leptin and glucocorticoids rapidly modulates synaptic excitation via endocannabinoid release. J Neurosci. 2006 ; 26: 6643-6650 (Pubitemid 44318346)
62. Maldonado R, Valverde O, Berrendero F. Involvement of the endocannabinoid system in drug addiction. Trends Neurosci. 2006 ; 29: 225-232
63. Matias I, Gonthier MP, Orlando P, et al. Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab. 2006 ; 91: 3171-3180 (Pubitemid 44271774)
64. Matias I, Petrosino S, Racioppi A, et al. Dysregulation of peripheral endocannabinoid levels in hyperglycemia and obesity: Effect of high fat diets. Mol Cell Endocrinol. 2008a ; 286: S66 - S78
65. Matias I, Vergoni AV, Petrosino S, et al. Regulation of hypothalamic endocannabinoid levels by neuropeptides and hormones involved in food intake and metabolism: insulin and melanocortins. Neuropharmacology. 2008b ; 54: 206-212 (Pubitemid 350299405)
66. Matsuda LA, Lolait SJ, Brownstein MJ, et al. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990 ; 346: 561-564
67. Melis T, Succu S, Sanna F, et al. The cannabinoid antagonist SR 141716A (Rimonabant) reduces the increase of extra-cellular dopamine release in the rat nucleus accumbens induced by a novel high palatable food. Neurosci Lett. 2007 ; 419: 231-235 (Pubitemid 46755483)
68. Morrison CD, Berthoud HR. Neurobiology of nutrition and obesity. Nutr Rev. 2007 ; 65: 517-534 (Pubitemid 351804334)
69. Morton GJ, Cummings DE, Baskin DG, et al. Central nervous system control of food intake and body weight. Nature. 2006 ; 443: 289-295 (Pubitemid 44435142)
70. Muccioli GG, Naslain D, Backhed F, et al. The endocannabinoid system links gut microbiota to adipogenesis. Mol Syst Biol. 2010 ; 6: 392
71. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993 ; 365: 61-65 (Pubitemid 23305569)
72. Murdolo G, Kempf K, Hammarstedt A, et al. Insulin differentially modulates the peripheral endocannabinoid system in human subcutaneous abdominal adipose tissue from lean and obese individuals. J Endocrinol Invest. 2007 ; 30: RC17 - RC21
73. Nogueiras R, Diaz-Arteaga A, Lockie SH, et al. The endocannabinoid system: role in glucose and energy metabolism. Pharmacol Res. 2009 ; 60: 93-98
74. Nogueiras R, Veyrat-Durebex C, Suchanek PM, et al. Peripheral, but not central, CB1 antagonism provides food intake-independent metabolic benefits in diet-induced obese rats. Diabetes. 2008 ; 57: 2977-2991
75. Osei-Hyiaman D, DePetrillo M, Pacher P, et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest. 2005 ; 115: 1298-1305 (Pubitemid 40629049)
76. Osei-Hyiaman D, Liu J, Zhou L, et al. Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice. J Clin Invest. 2008 ; 118: 3160-3169
77. Pagotto U, Marsicano G, Cota D, et al. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev. 2006 ; 27: 73-100 (Pubitemid 43228239)
78. Perwitz N, Wenzel J, Wagner I, et al. Cannabinoid type 1 receptor blockade induces transdifferentiation towards a brown fat phenotype in white adipocytes. Diabetes Obes Metab. 2010 ; 12: 158-166
79. Quarta C, Bellocchio L, Mancini G, et al. CB(1) signaling in forebrain and sympathetic neurons is a key determinant of endocannabinoid actions on energy balance. Cell Metab. 2010 ; 11: 273-285
80. Rinaldi-Carmona M, Barth F, Heaulme M, et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 1994 ; 350: 240-244 (Pubitemid 24268029)
81. Rowland NE, Mukherjee M, Robertson K. Effects of the cannabinoid receptor antagonist SR 141716, alone and in combination with dexfenfluramine or naloxone, on food intake in rats. Psychopharmacology (Berl). 2001 ; 159: 111-116
82. Sipe JC, Waalen J, Gerber A, et al. Overweight and obesity associated with a missense polymorphism in fatty acid amide hydrolase (FAAH). Int J Obes (Lond). 2005 ; 29: 755-759 (Pubitemid 40897010)
83. Soria-Gomez E, Matias I, Rueda-Orozco PE, et al. Pharmacological enhancement of the endocannabinoid system in the nucleus accumbens shell stimulates food intake and increases c-Fos expression in the hypothalamus. Br J Pharmacol. 2007 ; 151: 1109-1116 (Pubitemid 47195529)
84. Storr MA, Sharkey KA. The endocannabinoid system and gut-brain signalling. Curr Opin Pharmacol. 2007 ; 7: 575-582 (Pubitemid 350177551)
85. Strader AD, Woods SC. Gastrointestinal hormones and food intake. Gastroenterology. 2005 ; 128: 175-191 (Pubitemid 40039969)
86. Tam J, Vemuri VK, Liu J, et al. Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J Clin Invest. 2010 ; 120: 2953-2966
87. Tasker JG. Rapid glucocorticoid actions in the hypothalamus as a mechanism of homeostatic integration. Obesity (Silver Spring). 2006 ; 14 (Suppl 5). S259 - S265
88. Tedesco L, Valerio A, Cervino C, et al. Cannabinoid type 1 receptor blockade promotes mitochondrial biogenesis through endothelial nitric oxide synthase expression in white adipocytes. Diabetes. 2008 ; 57: 2028-2036
89. Thanos PK, Ramalhete RC, Michaelides M, et al. Leptin receptor deficiency is associated with upregulation of cannabinoid 1 receptors in limbic brain regions. Synapse. 2008 ; 62: 637-642 (Pubitemid 352032538)
90. Trojniar W, Wise RA. Facilitory effect of delta 9-tetrahydrocannabinol on hypothalamically induced feeding. Psychopharmacology (Berl). 1991 ; 103: 172-176
91. Tucci SA, Rogers EK, Korbonits M, et al. The cannabinoid CB1 receptor antagonist SR141716 blocks the orexigenic effects of intrahypothalamic ghrelin. Br J Pharmacol. 2004 ; 143: 520-523 (Pubitemid 39524268)
92. Turnbaugh PJ, Ley RE, Mahowald MA, et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006 ; 444: 1027-1031 (Pubitemid 46018515)
93. Verty AN, Allen AM, Oldfield BJ. The effects of rimonabant on brown adipose tissue in rat: implications for energy expenditure. Obesity (Silver Spring). 2009a ; 17: 254-261
94. Verty AN, Boon WM, Mallet PE, et al. Involvement of hypothalamic peptides in the anorectic action of the CB receptor antagonist rimonabant (SR 141716). Eur J Neurosci. 2009b ; 29: 2207-2216
95. Verty AN, McFarlane JR, McGregor IS, et al. Evidence for an interaction between CB1 cannabinoid and melanocortin MCR-4 receptors in regulating food intake. Endocrinology. 2004 ; 145: 3224-3231 (Pubitemid 38829994)
96. Wiedmer P, Nogueiras R, Broglio F, et al. Ghrelin, obesity and diabetes. Nat Clin Pract Endocrinol Metab. 2007 ; 3: 705-712 (Pubitemid 47463707)
97. Xue B, Kahn BB. AMPK integrates nutrient and hormonal signals to regulate food intake and energy balance through effects in the hypothalamus and peripheral tissues. J Physiol. 2006 ; 574: 73-83 (Pubitemid 43905798)
98. Yamanaka A, Beuckmann CT, Willie JT, et al. Hypothalamic orexin neurons regulate arousal according to energy balance in mice. Neuron. 2003 ; 38: 701-713 (Pubitemid 36694778)
99. Zbucki RL, Sawicki B, Hryniewicz A, et al. Cannabinoids enhance gastric X/A-like cells activity. Folia Histochem Cytobiol. 2008 ; 46: 219-224